Celyad SA PE Ratio 2014-2021 | CYAD

Current and historical p/e ratio for Celyad SA (CYAD) from 2014 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Celyad SA PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Celyad SA PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 4.46 inf
2021-06-30 5.26 0 0.00
2021-03-31 7.03 0 0.00
2020-12-31 7.80 0 0.00
2020-06-30 10.69 0 0.00
2019-12-31 10.42 0 0.00
2019-06-30 11.47 0 0.00
2018-12-31 18.16 0 0.00
2018-06-30 29.71 0 0.00
2017-12-31 43.10 0 0.00
2017-06-30 42.40 0 0.00
2016-12-31 17.76 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.074B $0.000B
Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86